Various USP7 inhibitors have been developed, and most recently selective USP7 inhibitors were generated that destabilize USP7 substrates including MDM2 and thereby increase TP53-mediated apoptosis of cancer cells (Kategaya et al., 2017; Turnbull et al., 2017). This evidence concerns the gene TP53 and cancer.